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Summary 
Background: The Meta-Analysis of Radiotherapy in squamous cell carcinomas of Head and neck has 
demonstrated that altered fractionation radiotherapy (AFRT) was associated with improved overall 
survival (OS) and progression-free survival (PFS) compared to conventional fractionation (CFRT). This 
update aims at confirming and explaining the superiority of hyperfractionared RT over the other 
AFRT regimens and at evaluating the benefit of altered fractionation within the context of 
concomitant chemotherapy with the inclusion of new trials. 
Methods: We searched bibliography databases, trials registries and meeting proceedings up to July 
2015 to identify published or unpublished randomized trials comparing CFRT to AFRT (comparison 1) 
or CFRT with concomitant chemotherapy to AFRT alone (comparison 2). Trials had to start 
randomization on or after January 1st 1970 and completed accrual before December 31st 2010, and 
included patients with non-metastatic squamous cell carcinoma. Trials including a non-conventional 
RT control arm, investigating hypofractionated RT or including mostly nasopharyngeal carcinomas 
were excluded. Trials were grouped in three types of fractionation: hyperfractionated, moderately 
accelerated and very accelerated. Individual patient data were collected and combined using a fixed-
effect model based on the intent-to-treat principle. Overall survival was the main endpoint. 
Findings: Comparison 1 included 33 trials and 11423 patients. AFRT was associated with a significant 
benefit on OS (hazard ratio (HR)=0.94 [95% confidence interval: 0.90; 0.98], p=0.0033). There was a 
significant interaction (p=0.051) between type of fractionation and treatment effect, the OS benefit 
being restricted to the hyperfractionated group (HR=0.83 [0.74; 0.92]) with absolute differences at 5 
and 10 years of +8.1% [+3.4; +12.8] and +3.9% [-0.6; +8.4]. PFS was improved by AFRT (HR=0.90 
[0.86; 0.94], p<0.0001), without significant difference between type of fractionation, through an 
improvement in local (HR=0.79 [0.72; 0.85]) and regional (HR=0.89 [0.81; 0.98]) control. Comparison 
2 included 5 trials and 986 patients. OS was significantly worse with AFRT compared to concomitant 
chemoradiotherapy (HR=1.22 [1.05; 1.42], p=0.0098) with absolute differences at 5 and 10 years of -
5.8% [-11.9; +0.3] and -5.1% [-13.0; +2.8]. 
Interpretation: This update confirms, with more patients and a longer follow-up, that 
hyperfractionated RT is, along with concomitant chemoradiotherapy, a standard of care for the 
treatment of locally advanced head and neck squamous cell cancers. The comparison between 
hyperfractionated RT and concomitant chemoradiotherapy remains to be specifically tested. 
Funding: Institut National du Cancer (PHRC); Ligue Nationale contre le cancer.  
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Introduction 
The modifications of radiotherapy (RT) fractionation have long been studied in various disease sites, 
including head and neck cancer. They are believed to be effective through two mechanisms that 
together improve the therapeutic ratio: the delivery of small fractions twice a day leads to the 
reduction of late toxicity that allows for higher total doses to be delivered, and the shortening of the 
overall treatment time limits tumor repopulation. Both strategies could improve tumor control rates. 
Numerous randomized trials have evaluated these RT schedules and provided conflicting results 
regarding tumor control and survival, mostly due to trial heterogeneity and limited sample size. 
These trials have however confirmed that fractionation modifications were usually associated with 
increased acute side effects but similar or lower late toxicity rates than conventional fractionation 
RT.1–4  
For squamous cell carcinoma of the head and neck, the Meta-Analysis of Radiotherapy in Carcinomas 
of Head and neck (MARCH) has demonstrated that altered fractionation RT (AFRT) was associated 
with improved overall survival (OS) and progression-free survival (PFS) when compared to 
conventional fractionation RT.1 Trials were grouped according to the type of altered fractionation 
used: hyperfractionation (HF), where a higher total dose in the same overall time than in the 
reference arm using twice daily fractions; moderate acceleration (Ac), where the total dose was 
unchanged (+/-5%) but delivered more quickly (generally approximately one week faster); and very 
accelerated RT with dose reduction (VAc), where RT duration was shortened by 50% or more, and 
total dose reduced. There was a significant interaction between treatment effect and altered 
fractionation regimens, the survival benefit being restricted to the HF subgroup.1 The reasons for the 
superiority of HF over other types of altered fractionation remained unclear, and HF has not become 
a standard of care, mostly due to logistical issues that favored the delivery of concomitant 
chemoradiotherapy (CRT) over HF.  
As several new trials have been published, an update of MARCH was performed, aiming at confirming 
and explaining the superiority of HF over the other altered fractionation regimens, evaluating the 
benefit of altered fractionation within the context of concomitant chemotherapy (CT) or post-
operative trials and providing a direct comparison with conventional fractionation concomitant CRT. 
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Methods 
This meta-analysis was performed according to a pre-specified protocol (available at 
https://www.gustaveroussy.fr/sites/default/files/march2-protocol.pdf). The method is similar to our 
previous publications.1,5–7 
Selection criteria and search strategy 
We searched PubMed, Web of Science, Cochrane Controlled Trials meta-register, ClinicalTrials.gov, 
and meeting proceedings up to July 2015 (Appendix page 2). To be eligible, published and 
unpublished trials had to compare primary or postoperative conventional fractionation RT to altered 
fractionation RT (+/- same concomitant CT in both arms) or conventional fractionation concomitant 
CRT to altered fractionation RT without concomitant CT. Trials had to be randomized in a way which 
precluded prior knowledge of treatment assignment, started randomization on or after January 1st 
1970 and completed accrual before December 31st 2010, and included patients with non-metastatic 
squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx undergoing first line 
curative treatment. Trials including a non-conventional RT control arm or including mostly 
nasopharyngeal carcinomas were excluded. Trials investigating hypofractionated RT, defined as 
doses per fraction above 2.5 Gy, were also excluded due to its use mostly in palliative cases. 
Procedures 
Individual patient data were requested for each eligible trial and for all randomized patients: patient 
and tumor characteristics, dates of randomization, failures and death, treatment arm allocated, 
details on treatments received, and acute and late toxicities. Follow-up information was updated 
whenever possible.  
All data were checked with a standard procedure6,8, which follows the recommendations of the 
Cochrane working group on meta-analysis using individual patient data. Internal consistency was 
checked (chronology of dates, outlier values, etc) and data were compared with trial protocol and 
published reports. Randomization validity was evaluated by checking patterns of treatment 
allocation and balance of baseline characteristics between treatment arms. Follow-up of patients 
was also compared between treatment arms.8 Every questions raised by the checking were discussed 
with the trialists. Each trial was reanalyzed and the analyses were sent to the trialists for validation. 
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Outcomes 
The primary endpoint was OS, defined as the time from randomization until death from any cause. 
The secondary endpoints were PFS, local (LF), regional (RF) and loco-regional failures (LRF) rates, 
distant failure (DF) rates, cancer and non-cancer mortality, and non-hematological toxicities. PFS was 
defined as the time from randomization to first progression (loco-regional or distant) or death from 
any cause. Living patients without events were censored at their date of last follow-up. Events 
considered were local failure alone for LF, regional failure or concomitant regional and local failures 
without distant failure for RF, distant failure either alone or combined with local or regional failures 
for DF. Only the first event was collected, meaning that patients with another failure event were 
censored at that time. Patients without failure events were censored at their time of last follow-up. 
Non-cancer mortality was defined as deaths without previous progression and resulting from known 
causes other than the treated head and neck cancer. Cancer mortality included deaths from any 
cause with previous progression and deaths from the treated head and neck cancer. Deaths from 
unknown cause without previous progression were considered as cancer mortality if they occurred 
within 5 years after randomization. Only trials with at least 80% of available data were considered 
eligible for non-hematological toxicity analysis. If at least 2000 patients were included in those trials, 
toxicity was analyzed. Moreover, for late toxicities, patients with a follow-up shorter than 6 months 
were excluded. 
Statistical Analysis 
All analyses were performed on an intention-to-treat basis. With 12000 patients (and at least 7000 
deaths), it would be possible to detect with a power of 99.9 % an absolute improvement in survival 
from 30 % to 33 % at 5-years (two-sided log-rank test, α=5%). Median follow-up was estimated with 
the reverse Kaplan-Meier method.9 Analyses were stratified by trial. Individual and overall pooled 
hazard ratios (HR) with 95% confidence intervals (CI) were calculated through a fixed-effect model 
using the log-rank expected number of events and variance.10 A similar model was used to estimate 
odds ratios (ORs) for the comparison of toxicity between groups, and incidences of toxicity in the 
experimental group were calculated using the incidence in the control group and the OR.10,11 χ² 
heterogeneity test and I² statistic were used to investigate the overall heterogeneity between trials.12 
In case of significant heterogeneity (p<0.10), trials whose 95% CI did not overlap with the 95% CI of 
the global HR were excluded. If heterogeneity was still significant, a random-effect model was used.6 
Methods used to estimate cancer and non-cancer mortality and to draw stratified curves were 
similar to the ones used in the previous meta-analysis.1,13,14 In addition to the fixed-effect model, a 
competing risk model was used for local failure, regional failure and distant failure 15. To estimate 5 
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and 10-years absolute differences, actuarial survival rates were computed on all patients and the 
hazard ratio at the corresponding time period was used to compute survival rates in each arm 1,13,14. 
Restricted mean survival times, a new method to estimate absolute benefit, were also estimated.16–18 
Details on those methods and power computation are reported in appendix page 3. 
Subset analyses were performed to study the interaction between treatment effect and trial level 
characteristics, using a test of heterogeneity among the different groups of trials. Residual 
heterogeneity within trial subgroups was computed by subtracting the χ² statistic of the 
heterogeneity test between groups from the χ² statistic of the overall heterogeneity test.19 
Predefined subsets were the altered fractionation regimen (HF, Ac or VAc), the use of concomitant 
CT and the performance of primary surgery. Interaction between treatment effect and patient 
subgroups (according to age, sex, performance status, primary site and overall stage) was estimated 
in a Cox model stratified by trial and containing treatment effect, covariate effect (for example age) 
and treatment-covariate interaction (“one-stage” model method).20  
All p-values were two-sided. Analyses were performed using SAS software, version 9.3 (SAS Institute, 
Cary, NC). 
Role of the funding source 
The funding sources had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. The submission of the paper for publication was decided by the MARCH 
collaborative group. PB, BL and JPP had access to the raw data. The corresponding author had full 
access to all of the data and bears the final responsibility to submit for publication. 
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Results 
Twenty-six new trials, published between 1995 and 2016, were identified. Data from four trials 
(n=185) were not collected: three21–23 due to the inability to contact investigators and one due to 
early closure with very limited follow-up.24 Five other trials were excluded after blind review by the 
steering committee, due to the absence of survival or randomization dates,25,26 issues with the 
randomization process27,28 or very short and different follow-up between groups,29 leaving 17 new 
trials, 15 published30–44 and two unpublished (CHARTWEL, EORTC 2296245). Two post-operative trials 
previously identified1 were also included46,47 and a third was excluded due to unavailable data48 
(Appendix page 16). Thus, 19 new trials were included (Table 1). Updated data could be obtained for 
nine trials2–4,49–54 included in the first MARCH round, increasing median follow-up from 6.1 
(interquartile range (IQR): 4.4; 8.0) to 10.4 (5.7; 15.2) years for the 15 previous trials.1 
Overall, 34 trials representing 11969 patients were included in the meta-analysis. The control arm of 
a four-arm trial4 was triplicated, a 2x2 trial (EORTC 2296245) and 3 three-arm trials represented 
respectively three and two relevant comparisons for the meta-analysis.36,37,55 The 33 trials included in 
the analysis of fractionation schedules (comparison 1) were divided into four predefined subgroups, 
depending on the type of radiotherapy: HF (8 comparisons, including the unpublished EORTC 
22962),4,33,44,45,49,50,56 Ac (19 comparisons),2,4,30,32,34–39,41,42,46,54,55,57–59 VAc (7 comparisons, including the 
unpublished CHARTWEL)3,47,51–53,60 and moderately hypofractionated (dose per fraction between 2-
2.5 Gy, 2 comparisons)31,40 (Appendix page 17). After discussion with the steering committee, the 
moderately hypofractionated trials were included in the Ac group. The analysis of altered 
fractionation RT versus conventional fractionation CRT (comparison 2) included 5 trials (four 
published36,37,43,55 and EORTC 2296245). Patients’ characteristics by trial are presented in appendix 
page 4. 
 
Thirty-three trials and 11423 patients (36 comparisons, 11981 patients) were included in comparison 
1. Median follow-up was 7.9 years (IQR: 5.3; 12.1); less than 5 years for 9 trials30, 35, 42, 44, 54,  56 
(including the two unpublished; 1706 patients); and greater than 10 years for 6 trials2,4,46,50,54,56 (3519 
patients). Patients were mostly male and had a performance status of 0 or 1. Median age was 59 
years (IQR: 52; 66). Tumors were mostly located in the oropharynx or larynx and were stage III-IV for 
75.0% (8986/11981) of the patients. Among stage I-II tumors, 70.0% (2045/2922) were laryngeal 
carcinomas. Patients’ characteristics are presented in appendix page 6. 
The results of all endpoints are summarized in Table 2. There were 8014 deaths (Appendix page 8). 
OS was improved by altered fractionation RT (HR=0.94 [95% CI: 0.90; 0.98], p=0.0033) with an 
absolute difference at 5 years of +3.1% [95% CI: +1.3; +4.9]. Heterogeneity between trials was not 
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significant (p=0.14, I2=20%). Interaction between the three altered fractionation regimens and the 
effect on OS was significant (p=0.051), the survival benefit being restricted to HF regimen (HR=0.83 
[0.74; 0.92]) with 5 years difference of +8.1% [+3.4; +12.8] (Figures 1 and 2). The HRs for the Ac and 
VAc regimens were respectively 0.96 [0.91; 1.01] and 0.95 [0.86; 1.06].  
Regarding PFS, 8758 patients have relapsed or died (Appendix page 9). PFS was improved by AFRT 
(HR=0.90 [0.86; 0.94], p<0.0001) with an absolute difference at 5 years of +3.7% [+2.0; +5.4] (Figures 
3 and 4). Interaction between altered fractionation regimens and the effect on PFS was not 
significant (p=0.17). Heterogeneity between trials was significant (p=0.045, I2=30%). The exclusion of 
the outlying CAIR trial58 removed heterogeneity (p=0.55, I2=0%), without modifying the overall HR 
and the interaction between altered fractionation regimens. 
There were 5789 cancer related deaths, 2225 non-cancer related deaths, and 2189, 1729 and 1326 
events respectively for local, regional and distant failures (Appendix page 9). AFRT was associated 
with significantly reduced cancer mortality, local and regional failures, with respective HRs of 0.91 
[0.86; 0.96] (p=0.00022), 0.79 [0.72; 0.85] (p<0.0001) and 0.89 [0.81; 0.98] (p=0.016). No differences 
were observed in terms of non-cancer mortality or distant failure, with respective HRs of 1.02 [0.94; 
1.11] (p=0.70) and 0.96 [0.86; 1.07] (p=0.43). Although no interaction was observed between altered 
fractionation regimens and the effect on local or regional control, HF was associated with a reduction 
of LF and RF; whereas Ac was only associated with a reduction of LF, and VAc had no effect on any of 
these endpoints (Table 2). Forest plots and survival curves are presented in appendix pages 19 to 27. 
Similar results were observed with competing risk methods for LF, RF and DF.  
Planned subset analyses showed that there was no significant interaction between the effect on OS 
and the period of accrual, i.e. included in the first round of MARCH versus in the present update 
(p=0.94), postoperative versus definitive RT (p=0.45) and trials including only larynx carcinomas 
versus the others (p=0.70). For the subset analysis regarding chemotherapy, five trials included the 
same concurrent chemotherapy in both treatment arms. The altered fractionation radiotherapy was 
HF for one trial that was terminated early 45 and MAc for the four others 30,36,39,42. None used 
adjuvant chemotherapy and only one used induction 42. The effect of altered fractionation 
radiotherapy was not different between trials with and without chemotherapy in both arms (p=0.39). 
Similar results were observed for PFS, except for a borderline interaction between AFRT effect on PFS 
and the administration, or not, of chemotherapy in both arm (p=0.073), the benefit of altered 
fractionation being limited to trials without chemotherapy (Appendix page 10). After the exclusion of 
the 9 comparisons with unusual RT regimens (hypofractionated RT,31,40 split course4,30,55,57 or both 
hyperfractionated and moderately accelerated RT44) or confounded CT schedules (different 
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chemotherapy regimens between arms)36,39, there was no significant interaction between type of 
fractionation and OS (p=0.11) (Appendix pages 28 and 29).   
Planned subgroup analyses showed a significant interaction between treatment effect on PFS and 
age (p=0.052). There was a reduction of treatment effect when age increased for PFS (p=0.016) and 
OS when follow-up was censored at 5-year (p=0.026). There was no interaction between treatment 
effect on OS or PFS and patient performance status, sex, site of primary and tumor stage (Appendix 
pages 11 and 13). In the subset of HF trials, no interaction with the five studied covariates was 
observed (data not shown). 
The effect of AFRT on regional control according to nodal status was studied as an unplanned 
analysis. In the 5592 node positive patients, there was a significant improvement in regional control 
with AFRT (HR=0.88 [0.79; 0.98], p=0.017) (Appendix page 30). The interaction between AFRT effect 
and radiotherapy fractionation regimens was borderline (p=0.060), in favor of the HF group with a HR 
of regional control of 0.67 [0.51; 0.89], compared to 0.96 [0.84; 1.09] and 0.81 [0.64; 1.03] for Ac and 
VAc respectively. 
An unplanned analysis was performed to evaluate the evolution of the AFRT effect over time 
(Appendix pages 31 and 32). The HR for death was 0.92 [0.87; 0.96] in the first five years after 
randomization, and 1.04 [0.93; 1.15] beyond 5 years, with a significant interaction between time and 
AFRT effect (p=0.034). Results were similar for PFS. The increase in restricted mean survival time in 
favor of AFRT at 5 and 10 years horizons was 1.5 months [95% CI: 0.5; 2.5] and 3.3 months [1.3; 5.4] 
for OS and 2.7 months [1.5; 3.9] and 4.9 months [2.7; 7.1] for PFS. When only hyperfractionated trials 
were analyzed, these increases were 3.9 months [1.9; 5.9] and 7.1 months [2.9; 11.3] for OS and 4.6 
months [2.4; 6.8] and 8.2 months [3.8; 12.5] for PFS. 
The toxicity analysis (Table 3) showed an increased prevalence of acute mucositis and need for 
feeding tube during treatment for patients treated with AFRT (OR=2.02 [95% CI: 1.81; 2.26] and 1.75 
[1.49; 2.05] respectively). Acute dermatitis was statistically increased only in the sensitivity analysis 
without trials responsible for the statistical heterogeneity (OR=1.20 [1.01; 1.42]). None of the late 
toxicities with sufficient available data (xerostomia, osteoradionecrosis, late mucosal toxicity, neck 
fibrosis) showed an increased prevalence with the use of AFRT.  
Five trials and 986 patients were included36,37,43,45,55 in comparison 2 (Table 1). Median follow-up was 
5.4 years (IQR: 4.7; 8.2), was less than 5 years for 2 trials37,45 (161 patients) and greater than 10 years 
for one trial43 (136 patients). One trial, which compared CRT to VAc, accounted for 57% (560/986) of 
patients and 59% (403/684) of deaths.36  Stage III and IV tumors were found in 21.9% (216/986) and 
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76.6% (755/986) of patients, respectively. The majority of tumors were located in the oropharynx 
(Appendix page 14). AFRT was associated with a significant decrease in OS compared to concomitant 
CRT (HR=1.22 [1.05; 1.42], p=0.0098) with an absolute difference at 5 years of -5.8% [-11.9; +0.3]. 
There was no significant heterogeneity between trials (p=0.87, I2=0%) (Figures 5 and Appendix page 
33). PFS was lower with AFRT (HR=1.26 [1.09; 1.45], p=0.0020) (Appendix pages 34 and 35). A 
decrease in locoregional control was observed with AFRT (HR=1.42 [1.16; 1.73], p=0.00054), with an 
absolute decrease at 5 years of - 9.9% [+2.7; +17.1]) but not for distant control (HR=0.99 [0.72; 1.37], 
p=0.95), Appendix pages 36 to 39). No specific analysis was performed for local or regional control 
due to a low number of patients in this comparison.    
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Discussion 
This updated individual patient data meta-analysis confirmed, with nearly twice as many patients and 
a longer follow-up than in the first round of the meta-analysis1, that AFRT was associated with a small 
but significant improvement in OS when compared with standard fractionation RT. However, this 
improvement in OS was modest in the overall population, +3.1% at 5 years, and was only significant 
in the HF group. Indeed there was a significant interaction between the effect on OS and altered 
fractionation regimens, and the absolute difference at 5 years was +8.1% for the HF group. The 
survival benefit decreased when age increased, but is otherwise consistent in all patient subgroups. 
There was a clear benefit on local control, a more limited benefit on regional (nodal) control and no 
benefit on distant metastases. AFRT was associated with increased acute mucositis and need for 
feeding tube placement but there was no significant difference in late toxicity. The new meta-
analysis of trials investigating the direct comparison between AFRT and concomitant CRT 
demonstrated the superiority of concomitant CRT regarding OS, PFS and locoregional control.  
The strengths of this meta-analysis are its size and the use of individual patient data, which allowed 
detailed checking of each trial that was subsequently re-analyzed and validated by the trialists. 
Unpublished trials were also included in order to avoid publication bias. Indeed, it is well known that 
positive trials are more frequently published than negative trials, especially in English medical 
literature 61,62. There was no significant overlap between our definitions of fractionation, meaning 
that a trial could be included in only one type of fractionation group. The steering committee was 
consulted if a discussion about the fractionation category was necessary. The intention-to-treat 
principle was respected for all analyses. The reproducibility of the findings regarding OS and PFS 
between the first round of the meta-analysis1 and the new trials included here, as demonstrated by 
the absence of interaction between meta-analysis round and treatment effect (OS: p=0.94; PFS: 
p=0.64), is an indicator of the robustness of the findings. At the time of this update, seven trials 
representing 3655 patients had a follow-up longer than 10 years,2,4,43,46,50,54,56 which allowed for long 
term analyses to be conducted. The large number of patients allowed secondary endpoints to be 
evaluated and subgroup and subset analyses to be done with adequate power.  
This second round of the meta-analysis provided a hypothetical explanation for the superiority of HF 
over the other altered fractionation regimens. HF was associated with a benefit both in local and 
regional control whereas accelerated regimens only provided an improvement in local control. When 
restricting the analysis to node positive patients, the interaction between altered fractionation 
regimens and regional control almost reached statistical significance (p=0.060) whereas it was not 
significant in the overall population (p=0.35). The explanation for this difference on nodal control 
favoring HF is unclear, but might be related to the increase in absolute dose provided by HF. Pure 
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acceleration should therefore be considered only for patients with a low nodal burden. Last, the 
collection of toxicity data allowed the analysis of the pattern of adverse events associated with AFRT.  
There are several limitations to this work. First, almost all of the trials used outdated radiotherapy 
(two or three dimensional), which is a concern since intensity modulated radiotherapy (IMRT) is the 
current standard of care for head and neck cancers. However the dose-intensity/efficacy relationship 
demonstrated here certainly remains valid even in the IMRT era given the fact that dose to gross 
tumor has not changed and is around 2 Gy per fraction. HF or acceleration can be performed with 
IMRT in the same way as they were done with 2D-RT and there is no reason to expect a different 
efficacy profile. They also outdate the Human Papilloma Virus (HPV) era and the collection of 
smoking status, which were available in very few trials of the meta-analysis. Since HPV-positivity is a 
major prognostic factor in oropharyngeal carcinoma 39, extensive analyses will be performed in trials 
that provided HPV/smoking data in the search for prognostic and predictive markers of fractionation 
modification efficacy (protocol: https://www.gustaveroussy.fr/sites/default/files/march2-hpv-
protocol.pdf). The trials’ accrual period ranged from 1979 to 2010 and this long time span might add 
heterogeneity in the meta-analysis, although no interaction between meta-analysis round and OS or 
PFS could be demonstrated. The second limitation concerns the quality of data collected for the 
toxicity analysis. Although this analysis was planned, it was based on a limited subset of trials for 
which this data were available, and was not feasible for comparison 2 due to insufficient data. Third, 
only 5 trials compared AFRT to standard RT with chemotherapy in both arms and 3 have a lower dose 
of chemotherapy in the arm with AFRT than in the standard RT arm.30,36,39 Last, the important 
number of endpoints analyzed raises the question of multiplicity of testing and the inflation of type I 
error. Overall survival was the primary endpoint of the meta-analysis. Regarding secondary 
endpoints, most analyses presented in this article were pre-specified. Subset (by trial characteristics) 
or subgroup (by patient characteristics) analyses are considered of lower level of evidence and 
mostly explanatory or hypothesis generating. The readers should pay careful attention to the 
consistency between the results obtained across the different endpoints, which reinforces the 
confidence in the analysis.  
The direct comparison between AFRT and concomitant CRT showed the superiority of the addition of 
concomitant chemotherapy over pure fractionation modification. This is providing an additional 
contribution to the bulk of randomized data having shown the superiority of CRT over RT alone.5 This 
is also in agreement with the results of a network meta-analysis performed previously where AFRT 
always ranked lower than concomitant CRT.63 Concomitant CRT should remain the standard of care 
for locally advanced node positive tumors. However, one should keep in mind that the altered 
fractionation regimens used in this direct comparison were HF for one trial 45,  Ac for three trials 
 14 
 
37,43,55 and VAc for one trial (majority of the data).36 Since HF appeared superior to the other altered 
fractionation regimens, the comparison between concomitant CRT and HF is relevant. It cannot be 
done with this meta-analysis due to the low number of patients in this comparison.  It remains to be 
performed and there is currently no suggestion that one would perform better than the other since 
the difference in OS at 5 years in favor of HF in this meta-analysis was 8.1% and very close to the one 
due to the addition of chemotherapy concomitant to RT which was 6.5% in the last update of the 
MACH-NC meta-analysis.5 A network meta-analysis is ongoing and will try to answer that question 
(protocol: https://www.gustaveroussy.fr/sites/default/files/machnc-network-protocol.pdf). 
Ongoing research efforts using the MARCH database include also extensive analysis of trials that 
provided information on the pathology findings for patients who have undergone primary surgery 
followed by postoperative RT. The findings might provide new insights into RT dose relationship in 
the postoperative setting which remains a controversial area.  
Other areas of improvement should include cost-effectiveness analyses comparing concomitant CRT 
and HF radiotherapy without concomitant chemotherapy, health services research to address 
patients’ and physicians’ difficulties in the implementation of HF radiotherapy, and better 
documentation of long term toxicity and patient reported outcomes.  
In conclusion, this updated individual patient data confirms the efficacy of AFRT over conventional 
fractionation RT and the superiority of hyperfractionated RT over the other AFRT schedules. The 
effect of acceleration is limited to local control, whereas HF appears to improve both local and 
regional control, and might thus be preferred for patients with node positive tumors. The direct 
comparison between AFRT and concomitant CRT suggests the superiority of concomitant CRT. Future 
research remains warranted to compare efficacy of hyperfractionated RT and concomitant CRT and 
to look for predictive markers of treatment efficacy. 
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Research in context 
Evidence before the study 
The Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) based on 15 trials and 
6515 patients has demonstrated that altered fractionation radiotherapy was associated with 
improved overall survival and progression-free survival when compared to conventional fractionation 
radiotherapy. For this update, we searched published and unpublished trials in PubMed, Web of 
Science, Cochrane Controlled Trials meta-register, ClinicalTrials.gov, and meeting proceedings, up to 
July 2015, without language restriction, for “randomized trials” of “radiotherapy fractionation” in 
“head and neck cancer”. Randomized trials comparing conventional fractionation radiotherapy to 
altered fractionation radiotherapy, or conventional fractionation radiotherapy with concomitant 
chemotherapy to altered fractionation radiotherapy alone were eligible. Trials had to start 
randomization on or after January 1st 1970 and completed accrual before December 31st 2010, and 
included patients with non-metastatic squamous cell carcinoma. Trials including a non-conventional 
RT control arm, investigating hypofractionated RT or including mostly nasopharyngeal carcinomas 
were excluded. Individual patient data were requested for each eligible trial. Risk of bias was checked 
with a standard procedure; each trial was reanalyzed and compared with trial protocol and published 
reports. Trials with quality issues were discussed with their investigators. For the trials previously 
included in the first round of MARCH, a follow-up update was requested.  
Added value of this study 
Individual patient data meta-analyses of randomized trials provide the highest level of evidence. This 
update of the MARCH meta-analysis has almost doubled the number of patients and trials included, 
reaching 34 trials and 11969 patients. The median follow-up was increased, being now 7.9 years 
overall (IQR: 5.3; 12.1) and 10.4 years (5.7; 15.2) for the trials previously included in the MARCH 
meta-analysis. Data on acute and late toxicity were collected. Finally, a separate meta-analysis was 
conducted that compared altered fractionation radiotherapy and concomitant chemoradiotherapy. 
Altered fractionation radiotherapy was associated with a significant benefit on overall survival. 
However the overall survival benefit being restricted to the hyperfractionated group due to a 
significant interaction between type of fractionation and treatment effect. Progression free survival 
was improved by altered fractionation radiotherapy, without significant difference between type of 
fractionation, through an improvement in local and regional control. Acute mucositis and the need 
for feeding tube during treatment were increased in the altered fractionation arm but late toxicities 
were similar between the arms. The second comparison demonstrated that altered fractionation 
radiotherapy had significantly lower overall survival compared to concomitant chemoradiotherapy, 
 16 
 
although trials altered fractionation regimens in this comparison were almost only accelerated 
radiotherapy, which has not been shown to increase survival.  
Implications of all the available evidence 
This updated meta-analysis confirms the efficacy of altered fractionation radiotherapy over 
conventional fractionation radiotherapy and the superiority of hyperfractionated radiotherapy over 
the other altered fractionation radiotherapy schedules. The effect of accelerated radiotherapy is 
limited to local control, whereas hyperfractionated radiotherapy appears to improve both local and 
regional control, and might thus be preferred for patients with node positive tumors.  
Hyperfractionated radiotherapy should therefore be considered a standard of care along with 
concomitant chemoradiotherapy for the treatment of locally advanced head and neck cancers. Head 
to head comparison between hyperfractionated radiotherapy and concomitant chemoradiotherapy 
are lacking. 
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Table 1: Description of the nineteen new trials 
Trialsref 
Inclusion 
period 
Sites Stage§§ 
Radiotherapy 
dose / duration 
No. weekly 
/ daily fractions 
Dose per 
fraction 
(Gray) 
No. 
fractions 
Chemotherapy 
drug/dose (mg/m²) 
No. patients 
analyzed / 
randomized 
Median 
follow-up 
in years 
(IQR) 
EORTC 2284330 1984-1987 
OC, OP, HP, L, 
O 
III/IV 
70 Gy /7 wks 5/wk; 1/day 2 35 
C: 6 mg/m²/day 
during 35 days 
53 / 53 
5.0 
(4.0 ; 5.2) 
72 Gy /7 wks sc wk 1,4,7; 3/day 1.6 45 
C: 10 mg/m²/day 
d1-5 on wk 1,4,7 
Cairo 199047 1990-1997 OC, OP, HP, L II-IV 
60 Gy / 6.0 wks po 5/wk; 1/day 2 30  
70 / 70 
3.8 
(1.6 ; 4.7) 46.2 Gy / 2 wks po 6/wk; 3/day 1.4 33  
CRT 90-00246 1991-1996 OC, OP, HP, L II-IV 
63 Gy / 7 wks po 5/wk; 1/day 1.8 35  
151 / 151 
13.8 
(8.0 ; 16.9) 63 Gy / 5 wks po 
5/wk; 1/day for 3 wks 
+ 10/wk; 2/day for 2 wks 
1.8 
+1.8 
15 
+20 
 
INRC-HN943§ 1992-1998 OC, OP, HP, L II-IV 
60 Gy / 6 wks sc 5/wk; 1/day 2 30 
C: 20 mg/m²/day 
on wk 1,4,7,10 
136 / 136 
18.5 
(16.6 ; 
20.8) 75 Gy / 6 wks 
5/wk; 1/day 
+ 5/wk; 1/day on wks 5-6 
2 
+1.5 
30 
+10 
 
Osaka 199331 1993-2001 L I 
60-66 Gy / 6-6.6 wks 5/wk; 1/day 2 30-33  
189 / 189 
5.9 
(4.6 ; 7.9) 56.25-63 Gy / 5-5.6 wks 5/wk; 1/day 2.25 25-28  
INRC-HN-1032 1994-2001 OC, OP, HP, L I-IV 
60 Gy / 6 wks po 5/wk; 1/day 2 30  
226 / 226 
4.5† 
(3.4 ; 6.2) 64 Gy / 5 wks po 
5/wk; 1/day 
(bid during wks 1 and 5) 
2 
+1.4/1.6 
25 
10 
 
EORTC2296245*§u 1996-1999 OC, OP, HP, L II-IV 
70 Gy / 7 wks 5/wk; 1/day 2 35  
57 / 57 
4.4 
(2.1 ; 4.9) 
80.5 Gy / 7 wks 10/wk; 2/day 1.15 70  
70 Gy / 7 wks 5/wk; 1/day 2 35 C: 100 mg/m², wk 1,4,7 
80.5 Gy / 7 wks 10/wk; 2/day 1.15 70 C: 100 mg/m², wk 1,4,7 
RTOG 951233 1996-2003 L II-IV 
70 Gy / 7 wks 5/wk; 1/day 2 35  
249 / 250** 
8.5 
(7.0 ; 10.7) 79.2 Gy / 6.5 wks 10/wk; 2/day 1.2 66  
ARTSCAN34 1998-2006 OC, OP, HP, L I-IV 
68 Gy / 6.5-7 wks 5/wk; 1/day 2 34  
750 / 750 
9.1 
(7.3 ; 11.4) 68 Gy / 4.5 wks 
5/wk; 1/day for 4.5 wks 
+ 5/wk; 1/day on wks 1-4 
2 
+ 1.1 
23 
+ 20 
 
IAEA-CRP-ACC35 1999-2004 OC, OP, HP, L I-IV 
66-70 Gy / 6.5-7 wks 5/wk; 1/day 2 33-35  
906 / 908** 
5.9 
(3.7 ; 8.2) 66-70 Gy / 5.5-6 wks 6/wk; 1/day 2 33-35  
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Trialsref 
Inclusion 
period 
Sites Stage§§ 
Radiotherapy 
dose / duration 
No. weekly 
/ daily fractions 
Dose per 
fraction 
(Gray) 
No. 
fractions 
Chemotherapy 
drug/dose (mg/m²) 
No. patients 
analyzed / 
randomized 
Median 
follow-up 
in years 
(IQR) 
DAHANCA 9 44 2000-2006 OP, HP, L I-IV 
66 Gy / 5.5 wks 6/wk; 1/day 2 33 
 77 / 77 
4.2 
(2.1 ; 5.2) 76 Gy / 5.5 wks 10/wk; 2/day 1.35 56 
GORTEC 9902§36 2000-2007 
OC, OP, HP, L, 
O 
III/IV 
70 Gy / 7 wks 5/wk; 1/day 2 35 
5FU : 600 mg/m²/day 
Cb: 70 mg/m²/day 
d1-4 on wk 1,4,7 
840 / 840 
5.2 
(4.9 ; 6.2) 
70 Gy / 6 wks 
5/wk; 1/day for 4 wks 
+ 5/wk; 2/day for 2 wks 
2 
+ 1.5 
20 
+ 20 
5FU: 600 mg/m²/day 
Cb: 70 mg/m²/day 
d1-5 on wk  1,4 
64.8 Gy / 3.5 wks 5/wk; 2/day 1.8 36  
TMH 1114§37 2000-2008 OP, HP, L II-IV 
66-70 Gy / 6-7 wks 5/wk; 1/day 2 33-35  
199 / NA 
4.5 
(2.0 ; 7.8) 
66-70 Gy / 6-7 wks 5/wk; 1/day 2 33-35 C: 30 mg/m²/wk, wks 1-7 
66-70 Gy / 5.5-6wks 6/wk; 1/day 2 35  
CHARTWELu 2001-2005 OC, OP, HP, L,O I-IV 
60-64 Gy / 6-6.5 wks po 1/day 2 30-32 
 114 / NA 
4.8 
(3.9 ; 5.4) 51-54 Gy / 2.4 wks po 5/wk; 3/day for 2.4 wks 1.5 30 
pCAIR38 2001-2004 OC, OP, L  I-IV 
63 Gy / 7 wks po 5/wk; 1/day 1.8 35 
 279 / 279 
7.2† 
(6.3 ; 8.0) 63 Gy / 5 wks po 7/wk; 1/day 1.8 35 
RTOG 012939 2002-2005 OC, OP, HP, L II-IV 
70 Gy / 7 wks 5/wk; 1/day 2 35 C: 100 mg/m², wk 1,4,7 
   738 / 743** 
7.9 
(7.0 ; 8.8) 72 Gy / 6 wks 
5/wk; 1/day for 6 wks 
+ 1/day for the last 12 days 
1.8 
+ 1.5 
30 
+ 12 
C: 100 mg/m²,wk1,4 
KROG 020140 2002-2010 L I/II 
66-70 Gy / 6.5-7 wks 5/wk; 1/day 2 33-35 
 156 / 156 
5.3 
(3.4 ; 6.7) 63-67.5 Gy / 5.5-6 wks 5/wk; 1/day 2.25 28-30 
POPART41 2003-2008 OC, OP, HP, L I-IV 
66Gy / 7 wks po 5/wk; 1/day 2 33 
 148 / 148 
6.3 
(5.3 ; 8.0) 66Gy / 5 wks po 
5/wk; 1/day for 2 wks 
+ 5/wk; 2/day for 3 wks 
2 
+ 1.8 and 1.3 
10 
+ 30 
CONDOR42 2009-2012 OC, OP, HP, L III/IV 
70Gy / 7 wks 5/wk; 1/day 2 35 C: 40 mg/m², wks 1-6 
56 / 56‡ 
2.8 
(1.8 ; 3.3) 70 Gy / 6 wks 6/wk for 6 wks 2 35 C: 40 mg/m², wks 1-6 
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ARTSCAN: Accelerated RadioTherapy of Squamous cell CArcinomas in the head and Neck, CAIR: Continuous Accelerated Irradiation,. CHARTWEL: Continuous 
Hyperfractionated Accelerated Radiation Therapy (CHART) Week-end-Less, CRT: Clinical Randomized Trial, CONDOR: Dutch Head and Neck Society 08-01, 
DAHANCA: Danish Head and Neck Cancer Group, EORTC: European Organisation for Research and Treatment of Cancer, GORTEC: Groupe d’Oncologie Radiothérapie 
Tête et Cou, IAEA-CRP-ACC: International Atomic Energy Agency Coordinated Research Projects ACCelerated, INRC-HN: Instituto Nazionale per la Ricerca sul Cancro-
Head and Neck, KROG: Korean Radiation Oncology Group, POPART: Post-Operative Accelerated RadioTherapy, pCAIR: post-operative Continuous Accelerated Irradiation 
(CAIR), RTOG: Radiation Therapy Oncology Group, TMH: Tata Memorial Hospital.  
C: Cisplatin, Cb: Carboplatin, d: day, Gy: Gray, HP: Hypopharynx, IQR: InterQuartile Range; L: Larynx, NA: Not Available, O: Other, OC: Oral Cavity, OP: Oropharynx, 
po: post-operative, sc: split course, wk/wks: week/weeks, 5FU: 5-Fluorouracil 
ref references used are those used in the paper  
* 2x2 design 
** 8 withdrew their consent in the two RTOG trials and in the IAEA trial and their data were not provided.  
† Follow-up significantly different between the two treatment groups; for INRC-HR 10, the medians of follow-up were respectively 4.2 (IQR: 3.5; 5.8) and 4.8 (3.4; 6.9) 
years in the control and experimental arm; for pCAIR, the medians of follow-up were respectively 6.8 (6.2; 7.8) and 7.6 (6.5; 8.5) years in the control and experimental arm. 
‡ 18 patients included in 2011 and 2012 
§ Included in comparison 1 and/or 2 (altered fractionated radiotherapy versus concomitant chemoradiotherapy); INRC-HN9 used alternated RT-CT with 3 series of RT (20 
Gy/2wk) at weeks 2–3, 5–6, and 8–9. 
§§ Stage computed using TNM and UICC classification 7th edition; may be different from trial’s publication 
u  Unpublished  
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Table 2: Summary of main results for trials comparing altered fractionation and conventional fractionation radiotherapy 
 
Overall 
survival 
Progression-free 
survival 
Cancer mortality 
Non-cancer 
mortality 
Local 
failure+ 
Regional 
failure+,£ 
Distant 
failure 
Hyperfractionated        
  No. events / No. patients 1313 / 1733 1413 / 1733 969 / 1733 344 / 1733 402 / 1729 289 / 1729 181 / 1729 
  Hazard ratio of treatment effect 
0.83 [0.74; 0.92] 
p=0.00063 
0.82 [0.74; 0.91] 
p=0.00019 
0.81 [0.72; 0.92] 
p=0.0014 
0.87 [0.70; 1.07] 
p=0.19 
0.80 [0.66; 0.98] 
p=0.029 
0.76 [0.61; 0.96] 
p=0.022 
0.96 [0.72; 1.29] 
p=0.80 
  Absolute difference at 5 years (%) +8.1 [+3.4; +12.8] +6.8 [+2.4; +11.2] -7.7 [-12.7; -2.7] -4.3 [-9.0; +0.4] -6.2 [-11.4; -1.0] -4.1 [-9.0; +0.87] +0.4 [-4.4; +5.2] 
  Absolute difference at 10 years (%) +3.9 [-0.6; +8.4] +4.0 [0.0; +8.0] NA NA NA NA NA 
Moderately accelerated        
  No. events / No. patients 5239 / 8159 5699 / 8159 3603 / 8159 1636 / 8159 1470 / 7555 1107 / 7366 829 / 7923 
  Hazard ratio of treatment effect 
0.96 [0.91; 1.01] 
p=0.14 
0.91 [0.87; 0.96] 
p=0.00077 
0.92 [0.86; 0.98] 
p=0.014 
1.05 [0.95; 1.16] 
p=0.32 
0.76 [0.69; 0.84] 
p<0.0001 
0.92 [0.82; 1.04] 
p=0.19 
0.96 [0.84; 1.10] 
p=0.55 
  Absolute difference at 5 years (%) +2.2 [0.0; +4.4] +3.3 [+1.1; +5.5] -2.9 [-5.2; -0.6] +0.4 [-1.8; +2.6] -6.0 [-8.3; -3.7] -0.8 [-2.8; +1.2] -0.7 [-2.7; +1.3] 
  Absolute difference at 10 years (%) +0.6 [-1.9; +3.1] +2.2 [-0.1; +4.5] NA NA NA NA NA 
Very accelerated        
  No. events / No. patients 1462 / 2089 1646 / 2089 1217 / 2089 245 / 2089 317 / 1429 331 / 1429 316 / 2058 
  Hazard ratio of treatment effect 
0.95 [0.86; 1.06] 
p=0.37 
0.91 [0.83; 1.01] 
p=0.069 
0.94 [0.84; 1.06] 
p=0.31 
1.01 [0.78; 1.31] 
p=0.92 
0.88 [0.70; 1.10] 
p=0.26 
0.89 [0.72; 1.11] 
p=0.31 
0.95 [0.76; 1.19] 
p=0.64 
  Absolute difference at 5 years (%) +1.8 [-2.5; +6.1] +1.6 [-2.1; +5.3] -2.0 [-6.5; +2.5]- +0.5 [-5.4; +4.4] -2.3 [-8.7; +4.1] NA -1.5 [-7.2; +4.2] 
  Absolute difference at 10 years (%) +0.4 [-4.4; +5.2] -0.3 [-4.3; +3.7] NA NA NA NA NA 
All types of fractionation        
  No. events / No. patients 8014 / 11981 8758 / 11981 5789 / 11981 2225 / 11981 2189 / 10713 1727 / 10524 1326 / 11710 
  Hazard ratio of treatment effect 
0.94 [0.90; 0.98] 
p=0.0033 
0.90 [0.86; 0.94] 
p<0.0001 
0.91 [0.86;0.96] 
p=0.00022 
1.02 [0.94; 1.11] 
p=0.70 
0.79 [0.72; 0.85] 
p<0.0001 
0.89 [0.81; 0.98] 
p=0.016 
0.96 [0.86; 1.07] 
p=0.43 
  Absolute difference at 5 years (%) +3.1 [+1.3; +4.9] +3.7 [+2.0; +5.4] -3.5 [-5.4; -1.6] -0.4 [-2.4; +1.4] -5.7 [-7.7; -3.7] -1.4 [-3.2; +0.4] -0.8 [-2.6; +1.0] 
  Absolute difference at 10 years (%) +1.2 [-0.8; +3.2] +2.3 [+0.5; +4.1] NA NA NA NA NA 
  Interaction between type of fractionation p=0.051 p=0.17 p=0.17 p=0.28 p=0.51 p=0.35 p>0.99 
  Heterogeneity between trials p=0.14, I²=20%* p=0.045, I²=30%* p=0.035, I²=32%* p=0.67, I²=0% p=0.0032, I²=45%† p=0.23, I²=15%‡ p=0.95, I²=0% 
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Results are presented with [95% confidence interval], Hazard ratios are:  altered fractionated RT versus conventional RT. NA: Not Available because not enough data at 10 
years 
Absolute variations are between survival rates for the overall and progression-free survival, between failure rates for local failure, regional failure and distant failure, and 
between mortality rates for cancer and non-cancer deaths. 
+ RTOG 7913 (210 patients), Cairo 1990 (n=70), TROG-9101 (350 patients) and GORTEC 9902 (n=559) did not distinguish between local and regional failure for all their 
patients. 
£ No regional failure but only local and distant failures for the Osaka 1993 trial (n=189).  
* No heterogeneity (I² = 0%) after the exclusion of one trial (CAIR58) 
† No heterogeneity (I² = 2%) after the exclusion of four trials (CAIR58, Rio49, TMH 111437, Osaka 199331) 
‡ No heterogeneity (I² = 1%) after the exclusion of one trial (Rio49)  
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Table 3: Acute and late severe toxicity between conventional and altered fractionation radiotherapy 
Severe toxicities are Grade 3-4 toxicities except for xerostomia where grade 2-3 were considered. “No heterogeneity” refers to a sensitivity analysis where trials responsible 
for statistical heterogeneity were excluded. The absence of change in the p-value for efficacy shows that the statistical significance is independent from the trial heterogeneity. 
Toxicity 
 
No. 
comparisons 
No. patients 
Toxicity rate in altered 
fractionated RT (%)* 
Toxicity rate in 
conventional RT (%) 
Odds Ratio 
[95% CI] 
p-value 
safety 
I² 
p-value 
heterogeneity 
Acute toxicities 
Mucositis 
All trials 20 8541 38.9 27.3 2.02 [1.81 ; 2.26] < 0.0001 78% < 0.0001 
No heterogeneity 16 7051 35.2 24.2 2.10 [1.84 ; 2.41] < 0.0001 0% 0.66 
Dermatitis 
All trials 15 4997 17.7 16.5 1.09 [0.93 ; 1.29] 0.29 36% 0.083 
No heterogeneity 13 4314 20.1 17.6 1.20 [1.01 ; 1.42] 0.041 0% 0.83 
Weight loss All trials 5 2053 3.6 4.2 0.87 [0.56 ; 1.36] 0.54 7% 0.37 
Need for feeding tube 
All trials 6 2859 52.1 39.7 1.75 [1.49 ; 2.05] < 0.0001 89% < 0.0001 
No heterogeneity 4 1871 35.6 27.1 1.63 [1.34 ; 1.99] < 0.0001 3% 0.38 
Late toxicities 
Xerostomia 
All trials 12 4726 51.3 51.1 1.01 [0.88 ; 1.14] 0.94 20% 0.25 
No heterogeneity 11 4414 54.6 54.1 1.02 [0.90 ; 1.17] 0.73 0% 0.50 
Bone toxicity All trials 11 3219 4.4 4.0 1.12 [0.80 ; 1.57] 0.52 0% 0.77 
Mucosal toxicity 
All trials 8 2298 14.5 13.4 1.10 [0.87 ; 1.40] 0.41 49% 0.058 
No heterogeneity 7 1921 14.4 14.9 0.96 [0.74 ; 1.24] 0.74 0% 0.64 
Neck fibrosis 
All trials 15 5557 7.6 6.9 1.13 [0.92 ; 1.39] 0.23 70% < 0.0001 
No heterogeneity 12 4250 7.0 6.5 1.09 [0.85 ; 1.38] 0.50 0% 0.45 
CI, confidence interval; RT, radiotherapy  
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Figure 1: Forest plot of overall survival for trials comparing altered fractionation and conventional 
fractionation radiotherapy 
See Table 1 for trials abbreviations 
 
The centre of each square is the hazard ratio (HR) for individual trials and corresponding horizontal line is the 
95% confidence interval (CI). The area of the square is proportional to the number of deaths in each trial. The 
broken line and centre of the black diamond is overall pooled HR and the horizontal tip of the diamond is the 
95% CI. Open diamonds are the HR of different types of radiotherapy. The exclusion of the outlying CAIR 
trial(58) reduced the heterogeneity further (p=0.89, I2=0%), increased the statistical interaction between altered 
fractionation regimens and survival (p=0.033) while not affecting the overall effect of altered fractionation 
radiotherapy on survival.   
CI: Confidence Interval, O–E: Observed minus Expected, RT: Radiotherapy, 
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Figure 2: Overall survival curves for trials comparing altered fractionation and conventional 
fractionation radiotherapy  
A: All radiotherapy types, B: Hyperfractionated, C: Moderately accelerated, D: Very accelerated 
A 
 
B 
 
C 
 
D 
 
CI: Confidence Interval, RT: Radiotherapy 
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Figure 3: Forest plot of progression-free survival for trials comparing altered fractionation and 
conventional fractionation radiotherapy 
See Table 1 for trials abbreviations  
 
CI: Confidence Interval, O–E: Observed minus Expected, RT: Radiotherapy 
  
 32 
 
Figure 4: Progression-free survival curves for trials comparing altered fractionation and conventional 
fractionation radiotherapy 
A: All radiotherapy types, B: Hyperfractionated, C: Moderately accelerated, D: Very accelerated 
A 
 
B 
 
C 
 
D 
 
CI: Confidence Interval, RT: Radiotherapy 
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Figure 5: Forest plots of overall survival for trials comparing altered fractionation radiotherapy and 
concomitant chemoradiotherapy (using conventional fractionation) 
See Table 1 for trials abbreviations  
 
CI: Confidence Interval, CRT: Chemoradiotherapy, O–E: Observed minus Expected, RT: Radiotherapy 
